한빛사논문
- 조회454
Hee Jin1, Michaela Jeong1, Gyeongseok Lee1, Minjeong Kim1, Youngjo Yoo1, Hyun Jin Kim2, Jaeho Cho,2* Yun-Sil Lee,1* and Hyukjin Lee1*
1College of Pharmacy, Graduate School of Pharmaceutical Sciences, Ewha Womans University, Seoul 03760, Republic of Korea
2Department of Radiation Oncology, Yonsei University Health System, Seoul 03722, Republic of Korea
H.J. and M.J. contributed equally to this work.
CORRESPONDING AUTHORS: Jaeho Cho, Yun-Sil Lee, Hyukjin Lee
Abstract
Pulmonary fibrosis is a chronic and irreversible lung disease with limited therapeutic regimens. Advances in elucidating the pathophysiological mechanism and discovering novel therapeutic interventions are still in urgent need. Here, the engineered lipid nanoparticles (LNPs) are developed for delivering RNA therapeutics to the lungs. Three different types of LNPs (native, cationic, and ligand incorporated) are optimized to facilitate the pulmonary delivery of RNAs. Among them, the mannose incorporated LNPs (Mannose LNPs) outperform the others and show efficient delivery of siRNAs down-regulating the epithelial-mesenchymal transition (EMT) associated protein, G2 and S phase-expressed protein 1 (GTSE1). Treatment with the mannose LNPs confirms a significant decrease in collagen accumulation and EMT-related proteins in the fibrosis animal models and provides functional recovery from pulmonary fibrosis. This approach demonstrates that engineered LNPs can facilitate the delivery of RNA therapeutics to the lungs and potentially open a new regimen of treatment for pulmonary fibrosis.
논문정보
- Research article
- 2022년 12월 (BRIC 등록일 2022-12-05)
- 국내 연구진
- 의약학 > 약학
댓글 작성 로그인
팝업 닫기관련 링크
관련분야 연구자보기
관련분야 논문보기
